Overview

Phase I Study of GW642444M in Healthy Japanese Male Subjects

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, placebo controlled, parallel-group, 7 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose of GW642444M from a novel dry powder device in healthy Japanese male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline